Most recent update: Friday, February 28, 2020 - 10:55

Bariatric News - Cookies & privacy policy

You are here

Stretta data

Stretta data presented at SAGES 2016

Important data and sessions at SAGES 2016 demonstrate safety, efficacy of Stretta therapy for GERD

Mederi Therapeutics has reported that new Stretta data was presented in multiple educational sessions at the recent 2016 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Boston. The company said that the data confirmed the feasibility and safety of Stretta Therapy for treating gastroesophageal reflux disease (GERD) in multiple patient populations.

Stretta is a transoral, non-surgical intervention that uses low power radiofrequency (RF) energy to remodel the muscle between the stomach and oesophagus. Studies demonstrate that Stretta resolves reflux symptoms, improves quality of life, reduces or eliminates medications, and decreases acid exposure in patients with chronic GERD.

Stretta therapy delivers low power, low temperature radiofrequency energy to remodel the valve known as the lower oesophageal sphincter (LES) at the junction of the oesophagus and the stomach. Stretta reduces or eliminates regurgitation of stomach contents by improving muscle tone and reducing random openings of the LES that are known to cause GERD. Stretta treatment results in elimination or significant reductions of GERD symptoms and medication use, and significant improvement in a patient's quality of life. (Credit: PRNewsFoto/Mederi Therapeutics Inc.)

Stretta was also featured in an expert panel discussing the problem of GERD in patients after bariatric surgery. In the panel, "What Every Surgeon Should Know about Reflux in the Bariatric Patient," Dr Dana Portenier, Chief, General Surgery, Duke Regional Hospital and assistant professor at Duke University School of Medicine, pointed out that Stretta may be an ideal option for patients with GERD post-bariatric surgery. Noting that revisional surgery for this patient can have significant complications, Portenier and other panel members remarked that Stretta is a less-invasive option that can help avoid revisional surgery while keeping future treatment options open.

New Stretta data from the UK was presented during the SAGES poster sessions. "A Prospective Study of Endoscopic RF Application (Stretta) for GERD: Early UK Experience," showed Stretta treatment resulted in symptomatic relief in the majority of patients. Mr Viswanath YKS and co-authors concluded that in selected patients with poor response to medications, Stretta is a safe and effective alternative to surgery. 

"GERD treatments were a hot topic at this year's SAGES meeting, Stretta was presented in multiple sessions as well as the hands-on course. It's clearly primetime for a treatment like Stretta. GERD is increasing, which, left untreated can lead to oesophageal cancer. At the same time there is a growing awareness of the dangers of long-term PPI use,” said company CEO Bob Knarr. “Stretta fills the need for a non-pharma and non-surgical option. Patients want more choices and with Stretta, physicians are able to provide a versatile option that is widely studied, and proven effective long-term."

Stretta Therapy has been proven safe and effective for the treatment of GERD in 37 studies from five continents, with studies showing up to ten years of durable symptom relief.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.